Targeting the skin for microneedle delivery of influenza vaccine

Advances in Experimental Medicine and Biology

Volumn 785, Issue , 2013, Pages 121-132

  Koutsonanos, Dimitrios G ^a   Compans, Richard W ^a   Skountzou, Ioanna ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; Influenza; Langerhans cells; Microneedles; Skin immunization

Indexed keywords

CYTOLOGY; EQUIPMENT; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; NEEDLE; REVIEW; SKIN; VACCINATION;

HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; NEEDLES; SKIN; VACCINATION;

MLCS; MLOWN;

EID: 84879012958     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6217-0_13     Document Type: Conference Paper

References (147)

1. Fiore, A.E., et al . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57, 1-60 (2008).
2. Monto, A.S. Seasonal influenza and vaccination coverage. Vaccine 28 Suppl 4, D33-44 (2010).
3. Osterholm, M.T. Preparing for the next pandemic. N Engl J Med 352, 1839-1842 (2005).
4. Thompson, W.W., et al . Influenza-associated hospitalizations in the United States. JAMA 292, 1333-1340 (2004).
5. Beigel, J.H. Influenza. Crit Care Med 36, 2660-2666 (2008).
6. Dushoff, J., Plotkin, J.B., Viboud, C., Earn, D.J. & Simonsen, L. Mortality due to influenza in the United States-an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 163, 181-187 (2006).
7. Heron, M. Deaths: leading causes for 2007. Natl Vital Stat Rep 59, 1-95 (2011).
8. Simonsen, L. The global impact of influenza on morbidity and mortality. Vaccine 17 Suppl 1, S3-10 (1999).
9. Palese, P. Influenza: old and new threats. Nat Med 10, S82-87 (2004).
10. Cox, N.J. & Subbarao, K. Influenza. Lancet 354, 1277-1282 (1999).
11. WHO. Immunization, Vaccines and Biologicals-Influenza. (2008).
12. Zhou, H., et al . Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54, 1427-1436 (2012).
13. Longini, I.M., Jr. & Halloran, M.E. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 161, 303-306 (2005).
14. Ompad, D.C., Galea, S. & Vlahov, D. Distribution of influenza vaccine to high-risk groups. Epidemiol Rev 28, 54-70 (2006).
15. Loerbroks, A., Stock, C., Bosch, J.A., Litaker, D.G. & Apfelbacher, C.J. Influenza vaccination coverage among high-risk groups in 11 European countries. Eur J Public Health (2011).
16. O'Brien, M.A., et al . Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 113, 585-593 (2004).
17. Izurieta, H.S., et al . Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 342, 232-239 (2000).
18. Nolan, T., et al . Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303, 37-46 (2010).
19. Avelino-Silva, V.I., et al . Campaign, counseling and compliance with influenza vaccine among older persons. Clinics (Sao Paulo) 66, 2031-2035 (2011).
20. Miraglia, J.L., et al . Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PloS one 6, e27214 (2011).
21. Mullooly, J.P., et al . Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 121, 947-952 (1994).
22. Nichol, K.L., et al . Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348, 1322-1332 (2003).
23. Reber, A.J., et al . Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. Aging Dis 3, 68-90 (2012).
24. Myers, E.R., Misurski, D.A. & Swamy, G.K. Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. Am J Obstet Gynecol 204, S128-140 (2011).
25. Blanchard-Rohner, G. & Siegrist, C.A. Vaccination during pregnancy to protect infants against influenza: why and why not? Vaccine 29, 7542-7550 (2011).
26. Ford, E.S., Mannino, D.M. & Williams, S.G. Asthma and influenza vaccination: findings from the 1999-2001 National Health Interview Surveys. Chest 124, 783-789 (2003).
27. Ford, E.S., Williams, S.G., Mannino, D.M. & Redd, S.C. Influenza vaccination coverage among adults with asthma: findings from the 2000 Behavioral Risk Factor Surveillance System. Am J Med 116, 555-558 (2004).
28. Plans-Rubio, P. Prevention and control of influenza in persons with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2, 41-53 (2007).
29. Hsu, A.C., See, H.V. & Wark, P.A. Innate immunity to influenza in chronic airways diseases. Respirology (2012).
30. Iorio, A.M., et al . Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine 24, 6624-6628 (2006).
31. Shaw, S.M., Williams, S.G., Yonan, N. & Fildes, J.E. Decreased immune responses to influenza vaccination in patients with heart failure. J Card Fail 15, 549; author reply 549-551 (2009).
32. Ott, S.R., et al . [The impact of viruses in lower respiratory tract infections of the adult. Part II: acute bronchitis, acute exacerbated COPD, pneumonia, and influenza]. Pneumologie 64, 18-27 (2010).
33. Hakim, H., et al . Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine 30, 879-885 (2012).
34. Bickel, M., et al . Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 24, F31-35 (2010).
35. Cooper, C., et al . Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PloS one 6, e17758 (2011).
36. Jain, S. & Chaves, S.S. Obesity and influenza. Clin Infect Dis 53, 422-424 (2011).
37. Camilloni, B., et al . An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 28, 7536-7541 (2010).
38. Potter, J.M., O'Donnel, B., Carman, W.F., Roberts, M.A. & Stott, D.J. Serological response to influenza vaccination and nutritional and functional status of patients in geriatric medical long-term care. Age Ageing 28, 141-145 (1999).
39. Clarke, C.E. & McComas, K. Seeking and processing influenza vaccine information: a study of health care workers at a large urban hospital. Health Commun 27, 244-256 (2012).
40. Potter, J., et al . Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 175, 1-6 (1997).
41. Carman, W.F., et al . Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 355, 93-97 (2000).
42. Music, T. Protecting patients, protecting healthcare workers: a review of the role of influenza vaccination. Int Nurs Rev 59, 161-167 (2012).
43. Medina, R.A. & Garcia-Sastre, A. Influenza A viruses: new research developments. Nat Rev Microbiol 9, 590-603 (2011).
44. Guan, R., et al . Structural basis for the sequencespecific recognition of human ISG15 by the NS1 protein of influenza B virus. Proc Natl Acad Sci USA 108, 13468-13473 (2011).
45. Sridharan, H., Zhao, C. & Krug, R.M. Species specificity of the NS1 protein of influenza B virus: NS1 binds only human and non-human primate ubiquitin-like ISG15 proteins. J Biol Chem 285, 7852-7856 (2010).
46. Higgins, R.R., et al . Recovery of Influenza B Virus with the H273Y Point Mutation in the neuraminidase Active site from a Human Patient. J Clin Microbiol (2012).
47. Ak, O., et al . Influenza B-associated encephalopathy in two adults. J Infect Chemother (2012).
48. Rath, B., et al . Virus Load Kinetics and Resistance Development during Oseltamivir Treatment in Infants and Children Infected with Influenza A (H1N1) 2009 and Influenza B Viruses. Pediatr Infect Dis J (2012).
49. Steininger, C., et al . Acute encephalopathy associated with influenza A virus infection. Clin Infect Dis 36, 567-574 (2003).
50. Baccam, P., Beauchemin, C., Macken, C.A., Hayden, F.G. & Perelson, A.S. Kinetics of influenza A virus infection in humans. J Virol 80, 7590-7599 (2006).
51. Canini, L. & Carrat, F. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85, 2764-2770 (2011).
52. Russell, C.A. The global circulation of seasonal influenza A (H3N2) viruses. Science 320, 340-346 (2008).
53. Russell, R.J., Stevens, D.J., Haire, L.F., Gamblin, S.J. & Skehel, J.J. Avian and human receptor binding by hemagglutinins of influenza A viruses. Glycoconj. J. 23, 85-92 (2006).
54. Skountzou, I. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J. Immunol. 185, 1642-1649 (2010).
55. Xu, R. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357-360 (2010).
56. Perez, D.R. Fitness of pandemic H1N1 and seasonal influenza A viruses during co-infection: evidence of competitive advantage of pandemic H1N1 influenza versus seasonal influenza. PLoS Curr. 1, RRN1011 (2009).
57. Chen, R. & Holmes, E.C. The evolutionary dynamics of human influenza B virus. J Mol Evol 66, 655-663 (2008).
58. Hampson, A.W. & Mackenzie, J.S. The influenza viruses. Med J Aust 185, S39-43 (2006).
59. Racaniello, V.R. & Palese, P. Isolation of influenza C virus recombinants. J Virol 32, 1006-1014 (1979).
60. Fouchier, R.A. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79, 2814-2822 (2005).
61. Tong, S., et al . A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA 109, 4269-4274 (2012).
62. Krauss, S., Walker, D. & Webster, R.G. Influenza virus isolation. Methods Mol Biol 865, 11-24 (2012).
63. CDC. Influenza Type A Viruses and Subtypes. (2011).
64. Khiabanian, H., Farrell, G.M., St George, K. & Rabadan, R. Differences in patient age distribution between influenza A subtypes. PloS one 4, e6832 (2009).
65. Pica, N., Chou, Y.Y., Bouvier, N.M. & Palese, P. Transmission of influenza B viruses in the guinea pig. J Virol 86, 4279-4287 (2012).
66. Sandbulte, M.R., et al . Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci USA 108, 20748-20753 (2011).
67. Stray, S.J. & Pittman, L.B. Subtype-and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin. Virol J 9, 91 (2012).
68. Yewdell, J.W. Viva la revolucion: rethinking influenza a virus antigenic drift. Curr Opin Virol 1, 177-183 (2011).
69. Salazar, M.I., Lopez-Ortega, O., Leon-Avila, G., Ramirez-Gonzalez, J.E. & Castro-Mussot, M.E. [The origin of the genetic variability of influenza viruses]. Gac Med Mex 146, 199-206 (2010).
70. Epstein, S.L. & Price, G.E. Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 9, 1325-1341 (2010).
71. Bouvier, N.M. & Palese, P. The biology of influenza viruses. Vaccine 26 Suppl 4, D49-53 (2008).
72. Grebe, K.M., Yewdell, J.W. & Bennink, J.R. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10, 1024-1029 (2008).
73. Szucs, T. The socio-economic burden of influenza. J Antimicrob Chemother 44 Suppl B, 11-15 (1999).
74. Molinari, N.A. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25, 5086-5096 (2007).
75. Monto, A.S. Seasonal influenza vaccinations: specialized products for different target groups. Vaccine 28 Suppl 4, D14-23 (2010).
76. Hannoun, C., Megas, F. & Piercy, J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103, 133-138 (2004).
77. Fiore, A.E., et al . Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59, 1-62 (2010).
78. Hanon, E. Vaccination strategies against influenza. Bull Mem Acad R Med Belg 164, 283-287 (2009).
79. Nichol, K.L. & Treanor, J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 194 Suppl 2, S111-118 (2006).
80. CDC. Seasonal Influenza (Flu). (2011).
81. Beyer, W.E., Nauta, J.J., Palache, A.M., Giezeman, K.M. & Osterhaus, A.D. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and metaanalysis. Vaccine 29, 5785-5792 (2011).
82. Gross, P.A. & Ennis, F.A. Influenza vaccine: splitproduct versus whole-virus types-How do they differ. N Engl J Med 296, 567-568 (1977).
83. Gross, P.A., et al . A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 136, 623-632 (1977).
84. Johansson, B.E. & Brett, I.C. Changing perspective on immunization against influenza. Vaccine 25, 3062-3065 (2007).
85. Cook, I.F., Barr, I., Hartel, G., Pond, D. & Hampson, A.W. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 24, 2395-2402 (2006).
86. Schwartz, B. & Wortley, P. Mass vaccination for annual and pandemic influenza. Current topics in microbiology and immunology 304, 131-152 (2006).
87. Fredrickson, K., et al . Influenza vaccination coverage among children aged 6-23 months -six immunization information system sentinel sites, United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 55, 1329-1330 (2006).
88. McElhaney, J.E. Influenza vaccine responses in older adults. Ageing Res Rev 10, 379-388 (2011).
89. Ellebedy, A.H. & Webby, R.J. Influenza vaccines. Vaccine 27 Suppl 4, D65-68 (2009).
90. Marcelin, G., et al . Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 202, 1634-1638 (2010).
91. Coudeville, L., et al . Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 10, 18 (2010).
92. CDC. Vaccine Effectiveness -How Well Does the Flu Vaccine Work? (2011).
93. CDC. Flu Vaccine Effectiveness: Questions and Answers for Health Professionals. (2011).
94. Kim, Y.C. & Prausnitz, M.R. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res 1, 7-12 (2011).
95. Jepps, O.G., Dancik, Y., Anissimov, Y.G. & Roberts, M.S. Modeling the human skin barrier -Towards a better understanding of dermal absorption. Adv Drug Deliv Rev (2012).
96. Skountzou, I. & Kang, S.M. Transcutaneous immunization with influenza vaccines. Current topics in microbiology and immunology 333, 347-368 (2009).
97. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
98. Romani, N., et al . Morphological and phenotypical characterization of bone marrow-derived dendritic Thy-1-positive epidermal cells of the mouse. J Invest Dermatol 85, 91 s-95 s (1985).
99. Itano, A.A., et al . Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19, 47-57 (2003).
100. Valladeau, J., et al . Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12, 71-81 (2000).
101. Allavena, P., et al . The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 177, 141-149 (2000).
102. Sozzani, S., Allavena, P., Vecchi, A. & Mantovani, A. Chemokines and dendritic cell traffic. J Clin Immunol 20, 151-160 (2000).
103. Locati, M., Allavena, P., Sozzani, S. & Mantovanii, A. Shaping and tuning of the chemokine system by regulation of receptor expression and signaling: dendritic cells as a paradigm. J Neuroimmunol 107, 174-177 (2000).
104. Sozzani, S., et al . In vitro and in vivo regulation of chemokine receptors. Eur Cytokine Netw 11, 502-503 (2000).
105. Romani, N., et al . Targeting skin dendritic cells to improve intradermal vaccination. Current topics in microbiology and immunology 351, 113-138 (2012).
106. Miller, L.S. Toll-like receptors in skin. Adv Dermatol 24, 71-87 (2008).
107. Abdelsadik, A. & Trad, A. Toll-like receptors on the fork roads between innate and adaptive immunity. Hum Immunol 72, 1188-1193 (2011).
108. Dupasquier, M., Stoitzner, P., van Oudenaren, A., Romani, N. & Leenen, P.J. Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse dermis. J Invest Dermatol 123, 876-879 (2004).
109. Debenedictis, C., Joubeh, S., Zhang, G., Barria, M. & Ghohestani, R.F. Immune functions of the skin. Clin Dermatol 19, 573-585 (2001).
110. Kubo, A., Nagao, K., Yokouchi, M., Sasaki, H. & Amagai, M. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med 206, 2937-2946 (2009).
111. Flacher, V., et al . Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol 130, 755-762 (2010).
112. Romani, N., Brunner, P.M. & Stingl, G. Changing views of the role of Langerhans cells. J Invest Dermatol 132, 872-881 (2012).
113. Flacher, V., et al . Skin Langerin(+) dendritic cells transport intradermally injected anti-DEC-205 antibodies but are not essential for subsequent cytotoxic CD8(+) T cell responses. J Immunol 188, 2146-2155 (2012).
114. del Pilar Martin, M., et al . Local response to microneedle-based influenza immunization in the skin. MBio 3, e00012-00012 (2012).
115. Raz, E., et al . Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 91, 9519-9523 (1994).
116. Koutsonanos, D.G., et al . Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 204, 582-591 (2011).
117. Prausnitz, M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56, 581-587 (2004).
118. Prausnitz, M.R., Mitragotri, S. & Langer, R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3, 115-124 (2004).
119. Kim, Y.C., Park, J.H. & Prausnitz, M.R. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev (2012).
120. Kim, Y.C., Jarrahian, C., Zehrung, D., Mitragotri, S. & Prausnitz, M.R. Delivery systems for intradermal vaccination. Current topics in microbiology and immunology 351, 77-112 (2012).
121. Koutsonanos, D.G., et al . Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2, 357 (2012).
122. Koutsonanos, D.G., et al . Transdermal influenza immunization with vaccine-coated microneedle arrays. PloS one 4, e4773 (2009).
123. Sullivan, S.P., et al . Dissolving polymer microneedle patches for influenza vaccination. Nat Med 16, 915v920 (2010).
124. Kim, Y.C., Quan, F.S., Compans, R.W., Kang, S.M. & Prausnitz, M.R. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. Journal of controlled release : official journal of the Controlled Release Society 142, 187v195 (2010).
125. Gill, H.S. & Prausnitz, M.R. Coating formulations for microneedles. Pharm Res 24, 1369-1380 (2007).
126. Gill, H.S. & Prausnitz, M.R. Coated microneedles for transdermal delivery. Journal of controlled release : official journal of the Controlled Release Society 117, 227-237 (2007).
127. Koyama, S., et al . Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2, 25ra24 (2010).
128. Chu, L.Y., Choi, S.O. & Prausnitz, M.R. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: Bubble and pedestal microneedle designs. J Pharm Sci 99, 4228-4238 (2010).
129. Lee, J.W., Park, J.H. & Prausnitz, M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 29, 2113-2124 (2008).
130. Chu, L.Y. & Prausnitz, M.R. Separable arrowhead microneedles. Journal of controlled release : official journal of the Controlled Release Society 149, 242-249 (2011).
131. Prausnitz, M.R., Mikszta, J.A., Cormier, M. & Andrianov, A.K. Microneedle-based vaccines. Current topics in microbiology and immunology 333, 369-393 (2009).
132. Choi, H.J., et al . Stability of influenza vaccine coated onto microneedles. Biomaterials 33, 3756-3769 (2012).
133. Patel, S.R., Lin, A.S., Edelhauser, H.F. & Prausnitz, M.R. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 28, 166-176 (2011).
134. Gupta, J., Denson, D.D., Felner, E.I. & Prausnitz, M.R. Rapid local anesthesia in humans using minimally invasive microneedles. Clin J Pain 28, 129-135 (2012).
135. Wang, P.M., Cornwell, M., Hill, J. & Prausnitz, M.R. Precise microinjection into skin using hollow microneedles. J Invest Dermatol 126, 1080-1087 (2006).
136. Gupta, J., Felner, E.I. & Prausnitz, M.R. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther 11, 329-337 (2009).
137. Banks, S.L., et al . Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci 99, 3072-3080 (2010).
138. Gupta, J., Felner, E.I. & Prausnitz, M.R. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther 13, 451-456 (2011).
139. Lee, J.W., Choi, S.O., Felner, E.I. & Prausnitz, M.R. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 7, 531-539 (2011).
140. Andrews, S., Lee, J.W., Choi, S.O. & Prausnitz, M.R. Transdermal insulin delivery using microdermabrasion. Pharm Res 28, 2110-2118 (2011).
141. Tas, C., et al . Delivery of salmon calcitonin using a microneedle patch. Int J Pharm 423, 257-263 (2012).
142. Song, J.M., et al . DNA Vaccination in the Skin Using Microneedles Improves Protection Against Influenza. Mol Ther (2012).
143. Kim, Y.C., et al . Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (2012).
144. Prow, T.W., et al . Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6, 1776-1784 (2010).
145. Fernando, G.J., et al . Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. Journal of controlled release : official journal of the Controlled Release Society 159, 215-221 (2012).
146. FDA. Influenza Virus Vaccine, Trivalent, Types A and B. (2012).
147. Norman, J.J. & Prausnitz, M.R. Improving patient acceptance of insulin therapy by improving needle design. J Diabetes Sci Technol 6, 336-338 (2012).